Faeth Therapeutics Signs Roche Collaboration on Breast Cancer Study
Faeth will sponsor and run a Phase 1b/2 study evaluating PIKTOR with Roche’s giredestrant in HR+/HER2- breast cancer.
Faeth will sponsor and run a Phase 1b/2 study evaluating PIKTOR with Roche’s giredestrant in HR+/HER2- breast cancer.